Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2026 08:30 ET | Source: NetworkNewsWire

NetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development Pathways

AUSTIN, Texas, April 24, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving...
April 21, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
April 14, 2026 07:30 ET | Source: Medicenna Therapeutics Corp.

Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...
February 23, 2026 08:30 ET | Source: NetworkNewsWire

NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios

AUSTIN, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in...
February 17, 2026 08:30 ET | Source: BioMedWire

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing...
January 26, 2026 09:00 ET | Source: Truveta

Truveta deepens oncology and scientific leadership with appointment of Johnathan Lancaster, MD, PhD as President and Chief Scientific Officer

BELLEVUE, Wash., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Truveta today announced the appointment of Johnathan M. Lancaster, MD, PhD as President and Chief Scientific Officer, deepening the company’s...
December 10, 2025 07:30 ET | Source: Medicenna Therapeutics Corp.

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case...
December 09, 2025 17:04 ET | Source: Medicenna Therapeutics Corp.

Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data

TORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
November 13, 2025 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on 10th December, 2025 Fondazion Melanoma Onus...
June 05, 2025 02:55 ET | Source: Alvotech

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...